QT monitoring in chemotherapy
Frontiers in Cardiovascular Medicine · 19.05.2026 · 13
DOI: 10.3389/fcvm.2026.1748382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 19.05.2026. Verfasst von Peter Y Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart, Lung, and Blood Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This review provides a comprehensive overview of cardiac electrophysiology principles as they apply to oncology care, with a focus on QT interval assessment and monitoring. Accurate measurement of the QT interval and appropriate heart rate correction—particularly using the tangent method and Fridericia formula—are essential for evaluating arrhythmic risk in cancer patients, who are especially vulnerable due to the cardiotoxic potential of many chemotherapeutic agents. We highlight key risk factors for QT prolongation, including electrolyte imbalances, underlying cardiac conditions, and concurrent use of QT-prolonging medications. Current cardiac monitoring protocols during chemotherapy are examined, with specific reference to clinical practices at The University of Texas MD Anderson Cancer Center. These practices underscore the importance of structured surveillance and timely intervention. Effective management requires a multi-pronged approach involving standardized measurement techniques, proactive risk stratification, and patient education. Counseling patients on symptoms such as palpitations, dizziness, or syncope facilitates early detection and evaluation. Given the expanding list of QT-prolonging agents, clinicians are encouraged to use resources like Torsades.org for up-to-date drug information. In the absence of formal guidelines for certain agents, institution-specific protocols defining thresholds for treatment initiation, dose adjustment, and monitoring frequency are critical for ensuring consistency, safety, and evidence-based decision-making in cardio-oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Förderung
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kim, P. Y., Ostos Mendoza, K. C., Kim, J. H., López Moreno, S. F., Casso-Chapa, B., Beinart, N. I., Paniagua-Bojorges, A., Ruesta Carrion, A. M., Lenz, S. A., Yusuf, S. W., Deswal, A., Palaskas, N. L., Koutroumpakis, E., Abe, J. I., & Ewer, M. S. (2026). QT monitoring in chemotherapy. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1748382
Vancouver
Kim PY, Ostos Mendoza KC, Kim JH, López Moreno SF, Casso-Chapa B, Beinart NI, et al. QT monitoring in chemotherapy. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1748382
BibTeX
@article{Kim2026,
author = {Kim, Peter Y and Ostos Mendoza, Keila Carolina and Kim, Jung Hyun and López Moreno, Silvia Fernanda and Casso-Chapa, Bernardo and Beinart, Noah I and Paniagua-Bojorges, Angelica and Ruesta Carrion, Andrea Mariana and Lenz, Stefania Assunto and Yusuf, Syed Wamique and Deswal, Anita and Palaskas, Nicolas L and Koutroumpakis, Efstratios and Abe, Jun-Ichi and Ewer, Michael S},
title = {QT monitoring in chemotherapy},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1748382}
}
EUVIMED